Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
CIA-Linked Investor Helped Quantum Systems Expand in US 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., April 03, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on April 2, 2018, the compensation committee of the Company’s board of directors granted one new employee an option to purchase 750 shares of the Company’s common stock with a per share exercise price of $44.20, the closing trading price on the grant date, and a restricted stock unit award for 500 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employee entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock options and restricted stock unit awards described above) for issuance under the Plan, which was approved by the Company’s Board of Directors in January 2017.
About Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
